Single-Cell Biotech completes ~￥100M Series A++ financing round, with WinX Capital serving as exclusive financial advisor

Recently, Single-Cell Biotech announced the completion of a new funding round amounting to nearly one hundred million. This round of financing was jointly invested by CASVC Investment Management, Zheshang Capital, and Shandong Finance. WinX Capital served as the exclusive financial advisor. The newly raised funds will be directed toward three strategic priorities: deep technology integration, intelligent ecosystem development, and global market expansion. This will comprehensively advance Single-Cell Biotech from the stage of "key technology breakthroughs and product commercialization" to a new phase characterized by instrument intelligence, industrial ecosystem integration, and globally networked applications.

As a global leader in providing solutions for live single-cell metabolic function analysis and sorting, Single-Cell Biotech leverages its proprietary and innovative "Meta-Ramanome Technology" as the core platform. Single-Cell Biotech has successfully developed a high-end product portfolio of live single-cell "metabolic profiling" instruments that target specific metabolic functions. This portfolio includes high-throughput Raman flow cytometric sorters, Raman microfluidic single-cell sorters, digital clone pickers, and single-cell microdroplet sorters. Together, these instruments establish a systematic and integrated solution spanning from scientific research to industrial applications. These original equipment offerings are widely applicable to microbial, plant, animal, and human cells. They not only enable the "detection, selection, cultivation, and utilization" of single cells with target metabolic functions but have also demonstrated strong industrial support capabilities across various application fields such as synthetic biology, industrial fermentation, environmental remediation, farmland protection, functional foods, precision nutrition, disease control, and human cell-based drug development.

Single-Cell Biotech will continue to deepen the integration of its Meta-Ramanome Technology with cutting-edge technologies such as microfluidics and automation. The company is committed to enhancing the precision, throughput, and user-friendliness of its "metabolic function-targeted" live single-cell analysis/sorting/cultivation/sequencing platform, driving its evolution from a laboratory instrument into a stable and efficient industrial-grade solution.

Single-Cell Biotech will also maintain a dedicated focus on core application scenarios, including synthetic biology, industrial fermentation, probiotics, and cell therapy. Its technology not only facilitates efficient microbial strain screening and process optimization but also provides live, non-destructive, single-cell metabolic dynamics data for the research, development, and quality control of cell-based therapeutics (such as CAR-T) and probiotics. This capability directly addresses the industry's core need for quantitative monitoring of cellular functions. By offering comprehensive support spanning from instrumentation to scenario-specific solutions, Single-Cell Biotech is establishing a solid technological foundation for the advancement of biomanufacturing systems and the development of the cell therapy industry.

To address core challenges in the field of single-cell metabolic phenomics—such as fragmented data, lack of standards, and difficulties in cross-study comparison—Single-Cell Biotech is actively developing the "Intelligent Cloud Expert System, RamanAI." This system aims to connect stakeholders across academia, industry, and research institutions. By promoting shared access to technical data, collaborative development of analytical models, joint research on industry standards, and real-time cloud-based analysis, it seeks to fundamentally resolve the industry-wide problem of "data silos."

The development and networking of "RamanAI" mark Single-Cell Biotech's evolution from a pure hardware equipment provider into an integrated platform solution provider offering "hardware + software + data services." This initiative is expected to lower the barrier to entry for single‑cell multi‑omics analysis and high‑throughput cellular resource mining technologies while significantly enhancing research and development efficiency in cell science and related industries.

In terms of global expansion, Single-Cell Biotech will engage deeply in and provide full support for the international scientific cooperation initiative – the in situ Metabolic Atlas of Single Cells (iMAPS.info) program. This initiative was launched by the Qingdao Institute of Bioenergy and Bioprocess Technology (QIBEBT) of the Chinese Academy of Sciences (CAS). It brings together nearly 70 global partners from academia, industry, and research institutions, including 45 national key laboratories and eight Fortune Global 500 companies. The program is dedicated to systematically analyzing and harnessing the metabolic functions of microbiomes at single‑cell resolution and on a global scale.

As a core provider of instrument platforms, Single-Cell Biotech's Meta‑Ramanome instrument series has become a key infrastructure component of the iMAPS program. Currently, the network has commenced construction and collaborative implementation across more than 60 sites worldwide. Through this collaboration, Single-Cell Biotech and its global user base are actively advancing the internationalization of Ramanome technical paradigms and data standards, achieving a leap from innovative instrument products to an internationally recognized standard system.